<DOC>
	<DOCNO>NCT00022958</DOCNO>
	<brief_summary>The primary objective study make Iodine-131 Anti-B1 Antibody broadly available patient . Secondary endpoint study obtain additional information efficacy safety Iodine-131 Anti-B1 Antibody .</brief_summary>
	<brief_title>Expanded Access Study Iodine-131 Anti-B1 Antibody</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients must histologically confirm diagnosis lowgrade NHL transform lowgrade NHL accord International Working Formulation Clinical Usage . ( The follow lowgrade histology include : small lymphocytic ; follicular , small cleave ; follicular , mixed smallcleaved large cell [ &lt; 50 % large cell component ] ) . Tumor must positive CD20 antigen . Patients must treat least one chemotherapy regimen relapse progress , fail achieve objective response ( CR PR ) last chemotherapy regimen . Patients must Karnofsky performance status least 60 % anticipated survival least 3 month . Patients must absolute granulocyte count great equal 1,500/mm3 , platelet count great equal 100,000/mm3 , require sustain support hematopoietic cytokine transfusion blood product . Patients must adequate renal function ( define serum creatinine &lt; 1.5 time upper limit normal ) , hepatic function ( defined total bilirubin &lt; 1.5 time upper limit normal ) , hepatic transaminase ( define AST &lt; 5 time upper limit normal ) . EXCLUSION CRITERIA : Patients mean &gt; 25 % intratrabecular marrow space involve lymphoma bilateral iliac crest bone marrow biopsy . Patients &lt; 10 % lymphoma involvement unilateral biopsy require bilateral biopsy . Patients receive cytotoxic chemotherapy , radiation therapy , immunotherapy , cytokine treatment within 4 week prior study entry ( 6 week nitrosourea compound ) exhibit persistent clinical evidence toxicity . Patients receive systemic steroid within 1 week study entry exclude , except patient maintenance steroid therapy noncancerous disease . Patients undergone treatment either stem cell bone marrow transplant . Patients active obstructive hydronephrosis . Patients evidence active infection require IV antibiotic time study entry . Patients New York Heart Association class III IV heart disease serious illness would preclude evaluation . Patients know HIV infection . Patients pregnant nursing . Males female must agree use contraceptive method enrollment 6 month receive Iodine131 AntiB1 Antibody . Patients prior malignancy lymphoma , except adequatelytreated skin cancer ( basal cell squamous cell carcinoma ) , situ cervical cancer , cancer patient diseasefree 5 year . Patients diseasefree another cancer great 5 year must carefully assessed time study entry rule recurrent disease . Patients progressive disease within 1 year irradiation arise field previously irradiated 3500 cGy . Patients previously receive radioimmunotherapy . Patients receive either approve nonapproved ( another protocol ) anticancer drug biologics . Patients know brain leptomeningeal metastasis . Patients HAMA positive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Radioimmunotherapy</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Corixa</keyword>
	<keyword>Bexxar</keyword>
	<keyword>Anti-B1 Antibody</keyword>
	<keyword>Tositumomab</keyword>
	<keyword>Iodine -131 Anti-B1 Antibody</keyword>
	<keyword>Iodine I 131 Tositumomab</keyword>
</DOC>